Close Sidebar
Nordic Life Science
Now Reading
Bavarian Nordic receives approval of extension of vaccine label to include monkeypox
Search for content, post, videos
Search for content, post, videos

Bavarian Nordic receives approval of extension of vaccine label to include monkeypox

August 4, 2022
555 Views
Paul Chaplin
The European Commission (EC) has extended the marketing authorization for the company’s smallpox vaccine, IMVANEX to include protection from monkeypox and disease caused by vaccinia virus. The approval, which follows a positive opinion by the Committee for Medicinal Products for Human Use (CHMP
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.

Malin Otmani

Related Posts

David Fredrickson
January 18, 2021

AstraZeneca and Daiichi Sankyo's Enhertu has been approved in the US for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. The approval by the Food and DrAlready a subscriber Login You have read all…

jallal
March 3, 2017

Medimmune and Sanofi Pasteur have announced an agreement to develop and commercialise MEDI8897, a monoclonal antibody (mAb) for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV,) jointly. MEDI8897 is currently in a Phase IIb clinical trial in prAlready a subscriber Login You have read all…

NNF Logo
February 27, 2018

Just before Christmas, the Novo Nordisk Foundation announced that it will establish a new centre, the BioInnovation Institute (BII), which aims to help the most talented researchers and entrepreneurs in developing and maturing research projects to a point at which they can attract capital on market Already a subscriber Login…

June 30, 2021

BioArctic's partner Eisai has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for lecanemab (BAN2401). BAN2401 is an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer’s disease. Based on a Phase 2Already a subscriber Login You have read all your free…